skip to content

Sustainability targets and performance

We have developed targets and are measuring performance to drive impact across our three key areas of focus.

Researchers conducting clinical trials in a controlled, professional environment.

Access to innovation

We want to maximise access to our innovation and support equitable health outcomes for patients worldwide.

Read more on access targets
A diverse group of people collaborates around a laptop, engaged in discussion and sharing ideas.

People

We are committed to fostering a work environment where all people are valued and have the opportunity to thrive.

Read more on people targets
Aerial view of a large solar farm with rows of blue solar panels harnessing renewable energy.

Environment

We aim to make a positive and meaningful contribution to the health of nature, water systems, climate & people.

Read more on environment targets

Access to innovation targets

3x

Triple number of patients treated with our strategic pharmaceuticals portfolio by 2029 (base year 2023).

2x

Double number of patients reached with our high-medical-value diagnostics solutions by 2029 (base year 2020).

2x

Double number of patients receiving our core pharmaceutical therapies in low- and lower-middle-income countries3 by 2026 (base year 2021).

3x

Triple societal impact delivered with our strategic pharmaceuticals portfolio by 2029 (base year 2023).

Access to innovation key achievements

[Icon]

39 million +

Patients treated with our medicines in 20251.

[Icon]

258 million +

Patients reached with our high-medical value diagnostics solutions in 20252.

[Icon]

59,000 +

Patients in low- and lower-middle-income countries3 received our core pharmaceutical therapies in 2025, compared to 27,000 in 2021 - achieving our goal one year ahead of schedule.

1 Representing a 62% increase from the previous year; in addition, we registered a 28% growth in patients treated with our strategic pharmaceuticals portfolio, keeping us firmly on track to triple our reach by 2029.

2 Representing a 15% increase from the previous year and outperforming our target for 2029.

3 Low- and lower-middle-income countries covered by our access goal are Egypt, Indonesia, Morocco, and Vietnam.

People targets

> 75

Health and Well-being Index score in our global employee survey by 2029.

> 80

Inclusion Index score in our global employee survey by 2029.

People key achievements

[Icon]
[Icon]

Health & wellbeing

  • Advancing global mental health and well-being strategy. 

  • Monitoring and analysing the Health and Well-being Index.

Inclusion

  • Implementing global inclusion and belonging strategy. 

  • Monitoring and analysing the Inclusion Index.

Climate change targets

- Net zero GHG emissions across the value chain (scope 1-3) by 2045
- Absolute zero GHG emissions in own operations (scope 1-2) by 2050

- 90%

in absolute scope 1, 2 and 3
GHG emissions by 2045
(base year 2022).

- 70%

in absolute scope 1 and 2
GHG emissions by 2029
(base year 2022).

- 22.5%

in absolute scope 3*
GHG emissions by 2029
(base year 2022).

70%

of suppliers to have
science-based targets
by 2029.

[Logo]

*From fuel & energy, waste from company operations and business travel, as well as from the use of sold products and the end of life of sold products.

Read more about our detailed environmental goals.

Climate change key achievements

Scope 1 & 2 GHG emissions
Decorative Illustration

Scope 1, 2 and 3 GHG emissions
Scope 1,2 and 3 GHG emissions (ktCO2e)

Scope 3 GHG emissions
Scope 3 GHG emissions (ktCO2e) – Categories 3, 5, 6 and Categories 11, 12

Supplier engagement
Supplier engagement

100% sustainable electricity across our sites in 2025.

For further information on how Roche defines and reports climate-related claims, please refer to our Climate-Related Claims Disclosure Statement.

Product sustainability targets

Reducing GHG emissions

by 22.5% from product use and end-of-life treatment by 2029 (base year 2020).

Reducing product environmental impact

by 50% by 2029 - measured by Product Sustainability Performance tool (PSP) (base year 2020).

Integrating sustainability criterias

by 2028 for all product-related decision making processes across the product life cycle.

Meeting sustainability criterias

of their product family for all products by 2045.

Product sustanability key achievements

[Icon]

GHG emission from product use and end-of-life treatment

  • Embedding eco-design and recyclability improvements across the product life cycle.

  • Increasing energy efficiency in diagnostic equipment during the use phase


[Icon]

Environmental impact of our products

  • Measuring progress with a subset of products that represent the product portfolio.

  • Defining broad sustainability criteria for all Roche products.


[Icon]

Embedding sustainability into product decision-making

  • Embedding product sustainability criteria into product design processes.

  • Integrating PSP scoring into product governance.

  • Expanding the application of life cycle assessment methodologies.


[Icon]

Advancing product sustainability criteria

  • Expanding application of product sustainability criteria to all products.

  • Establishing improvement targets by product family.


Biodiversity and water targets

Certified for biodiversity and water stewardship

by 2030 of relevant Roche sites and key suppliers through their projects.

Procuring from credible certified sources

by 2030 for key natural commodities.

Incorporating true costs

of water and natural commodities into business decisions by 2045.

Reduction in phosphorus emissions

to wastewater by 64% by 2029 (base year 2025).

Reduction in Roche's risk-weighted water consumption

by -5% by 2029 (base year 2025).

Read more about our detailed environmental goals.

Biodiversity and water key achievements

[Icon]

Biodiversity and water stewardship certification

  • Defining high-risk sites and suppliers guided by using the Science Based Targets Network (SBTN)-aligned methodology.

  • Pursuing water stewardship certification.


[Icon]

Certified sourcing of key natural commodities

  • Defining our key natural commodities through an assessment guided by the SBTN and TNFD frameworks.

  • Identifying high-impact materials and evaluating available certification schemes


[Icon]

True cost of water and natural commodities

Developing methodologies and baseline data to capture the real cost of water- and nature- related dependencies, which will inform future strategic decisions.

[Icon]

Reduction of phosphorus emissions to wastewater

Minimising pollution of nutrient discharge to receiving waters.

Decorative Illustration

Water efficiency

Tailored initiatives being implemented at sites to improve water efficiency, including water recycling, closed-loop systems and efficiency upgrades.

Roche’s Annual Report 2025

Discover how we're revolutionising patient care in our 2025 Annual Report. Focused on innovation, research, sustainability, and strategic partnerships, with insights into our groundbreaking approaches.

Read more

Discover more

Positions, policies & downloads

Download our policies, guidelines, positions and other documents.

Sustainability at Roche

At Roche, our ambition lies not only in transforming healthcare, but also in our contributions to environmental protection, supply chain sustainability, social commitment and philanthropy.